J&J Sees Double-Digit Growth Ahead Amid Strong New Drug Pipeline

Johnson & Johnson's stock price has surged by 55.5% over the past year, outperforming the S&P 500's 20.7% return. The company's pharmaceutical segment is driving this growth, thanks to strong performances from newer drugs and optimism about recent FDA approvals and clearances.

CEO Joaquin Duato highlighted three promising new medications during a second-quarter earnings call: Icotyde, Inlexzo, and Rybrevant. He expressed confidence that these launches will continue to accelerate momentum into 2027 and beyond, with a 'line of sight to double-digit growth by the end of the decade.'

One analyst projects that Inlexzo could reach $2.4 billion in sales by 2028, making it a significant driver of revenue for the company.